Revolution Medicines, Inc. announced on December 2, 2024, key clinical updates from its RAS(ON) inhibitor portfolio, highlighting progress across multiple programs. Updated Phase 1 data for RMC-6236 monotherapy in previously treated metastatic pancreatic ductal adenocarcinoma (PDAC) showed a median PFS of 8.8 months for KRAS G12X mutations at the 300 mg QD dose, supporting the ongoing Phase 3 RASolute 302 trial.
In non-small cell lung cancer (NSCLC), updated data for RMC-6236 monotherapy in 124 previously treated RAS mutant patients demonstrated favorable dose intensity and compelling PFS and OS, supporting the planned Phase 3 RASolve 301 trial. Additionally, initial data for RMC-6236 combined with pembrolizumab in NSCLC showed acceptable tolerability and activity, supporting further evaluation in first-line settings.
The company also reported initial clinical safety, tolerability, and activity for the RAS(ON) inhibitor doublet of RMC-6291 and RMC-6236 in previously treated KRAS G12C colorectal cancer patients, achieving a 25% objective response rate and 92% disease control rate in an evaluable subset. These results provide proof-of-mechanism for the doublet strategy and support its continued development across various tumor types.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.